Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $441.8 million
Deal Type : Licensing Agreement
Boehringer Licenses New Compound for Fibro-Inflammatory Diseases from Kyowa Kirin
Details : Under the terms of the agreement, Boehringer Ingelheim will receive exclusive, worldwide rights from Kyowa Kirin to develop novel, first-in-class treatments for fibro-inflammatory diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 01, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $441.8 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Argenx
Deal Size : Undisclosed
Deal Type : Partnership
Argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships
Details : Argenx and Chugai have entered into a research license and option agreement under which argenx may access Chugai’s SMART-Ig® and ACT-Ig®.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
June 10, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Argenx
Deal Size : Undisclosed
Deal Type : Partnership